Research &


Creating Innovative Clinical Programs

At Cullinan, our model is unique: we identify high impact targets and then pursue the best modality to address each identified target, focusing on molecules that inhibit key drivers of disease, or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. This methodology has resulted in a broad and deep pipeline of clinical-stage programs with diverse targets, mechanisms, and modalities.

By frontloading scientific experimentation early in the development of our assets, we can rigorously define decision points for advancement or discontinuation to bring forward only the most promising therapies, ensuring efficiency in both the preclinical and clinical development processes.

Through robust translational research, we develop a deep understanding of mechanisms of action, dosing parameters, and potential mitigations of toxicity in the early development phase to fully inform our approach in th clinic.

At Cullinan Therapeutics, we are creating robust clinical programs by:
Image of Circles
Building strong clinical development capabilities to move our assets through the development journey with in-house expertise, strong investigator collaboration, and early engagement with key opinion leaders to understand the clinical application of our science.
Employing robust biomarker plans and real-time access to data emerging from our clinical trials to support efficient and smart clinical decision-making.
Designing strategic combination experiments early in development to understand the broader potential beyond monotherapy and to garner insights as to whether our programs can be best utilized with other agents.

Our Research and Discovery Process

Step 1: Discover

We aspire to be led by innovation that transcends traditional drug development borders, whether from our own discovery efforts or through exceptional engagement with our academic, health center, and industry partners.

Step 2: Develop

We leverage our scientific excellence to create differentiated ideas, identify unique targets, and select the optimal modality to develop transformative therapeutics across a wide variety of cancer and autoimmune indications.

View Our Current

Step 3: Deliver

We are building a pipeline of molecules that have the potential to be best- or first-in-class, allowing us to deliver on our promise to create new standards of care and bring new therapeutic solutions to patients.

Discover Our
Diverse Pipeline

Our Promise: Delivering on Patient Benefit

Our clinical trials are designed with clinically relevant endpoints and predefined benchmarks for success.

Collaboration Is Key

Strong partnerships result in innovative clinical programs.